Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Chief Scientific Officer | September 09, 2020 | September 10, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
X4 Pharmaceuticals, Inc
Report date September 09, 2020 · Filed September 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,076 |
Reported balance
After 2020-09-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-09-09 · Sale · Disposed 5,834 · Balance 42,076 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2: Includes sale of 1,660 shares to cover personal income tax obligation upon settlement of restricted stock unit award. F3: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $7.57 to $8.96, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4: Of the shares of common stock reported, 11,666 shares represent unvested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2: Includes sale of 1,660 shares to cover personal income tax obligation upon settlement of restricted stock unit award.
F3: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $7.57 to $8.96, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: Of the shares of common stock reported, 11,666 shares represent unvested restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2020 Filed Sep 10, 2020 12:36 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | SaleCommon Stock | 5,834 | $8.05 | $46,963.70 |
DisclosureSEC source: 0001628280-20-013423 · wf-form4_159974138846947.xml · nonDerivative · entry 1 Skerlj Renato · CIK 0001814632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,076 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · shares: Includes sale of 1,660 shares to cover personal income tax obligation upon settlement of restricted stock unit award. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $7.57 to $8.96, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Of the shares of common stock reported, 11,666 shares represent unvested restricted stock units. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 00:14 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-012844 · wf-form4_159779605540870.xml · nonDerivative · entry 2 Skerlj Renato · CIK 0001814632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,910 F3 · shares: Represents restricted stock units issued to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date. One third of the shares underlying the restricted stock unit award vested on August 17, 2020. One third of the shares will vest on August 17, 2021, and one third of the shares will vest on August 17, 2022, subject to the Reporting Person providing continuous service to the Issuer on such dates. Shares in respect of the vested portion of the award must be delivered no later than March 15 of the calendar year following the year in which vesting occurs. F4 · balance_after: Of the shares of common stock reported, 11,666 shares represent unvested restricted stock units. Read SEC document |
| August 14, 2020 Filed Aug 19, 2020 00:14 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-012844 · wf-form4_159779605540870.xml · nonDerivative · entry 1 Skerlj Renato · CIK 0001814632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,160 F1 · shares: Represents restricted stock units issued to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date. One third of the shares underlying the restricted stock unit award vested on August 14, 2020. One third of the shares will vest on August 14, 2021, and one third of the shares will vest on August 14, 2022, subject to the Reporting Person providing continuous service to the Issuer on such dates. Shares in respect of the vested portion of the award must be delivered no later than March 15 of the calendar year following the year in which vesting occurs. F2 · balance_after: Of the shares of common stock reported, 5,833 shares represent unvested restricted stock units. Read SEC document |
| June 10, 2020 Filed Jun 11, 2020 21:32 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $8.69 | $0.00 |
DisclosureSEC source: 0001628280-20-009293 · wf-form4_159191113695970.xml · derivative · entry 1 Skerlj Renato · CIK 0001814632 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-06-09 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on June 10, 2021, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option on the last day of each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.